cvt 124 has been researched along with Cardiac Failure in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gottlieb, SS | 1 |
| Dohadwala, MM; Givertz, MM | 1 |
| Miracle, C; Thomson, S; Vallon, V | 1 |
| Beckman, E; Bennett, D; Cines, M; Fisher, ML; Freudenberger, R; Gladwell, T; Gottlieb, SS; Liittschwager, EB; Marshall, J; Skettino, SL; Wolff, A | 1 |
| Abraham, WT; Beckman, E; Bennett, D; Bourge, R; Brater, DC; Dyer, F; Goldman, S; Gomez, M; Gottlieb, SS; Havranek, E; Thomas, I; Ticho, B | 1 |
| Crawford, FA; Escobar, GP; Hendrick, JW; Lucas, DG; Mukherjee, R; Sample, JA; Smits, GJ; Spinale, FG | 1 |
3 review(s) available for cvt 124 and Cardiac Failure
| Article | Year |
|---|---|
Adenosine A1 antagonists and the cardiorenal syndrome.
Topics: Adenosine A1 Receptor Antagonists; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Furosemide; Glomerular Filtration Rate; Heart Failure; Humans; Kidney Diseases; Kidney Function Tests; Male; Mice; Prognosis; Randomized Controlled Trials as Topic; Receptor, Adenosine A1; Risk Assessment; Severity of Illness Index; Syndrome; Treatment Outcome; Xanthines | 2008 |
Role of adenosine antagonism in the cardiorenal syndrome.
Topics: Adenosine A1 Receptor Antagonists; Animals; Heart Failure; Hospital Mortality; Humans; Kidney Failure, Chronic; Registries; Syndrome; Xanthines | 2008 |
Adenosine and kidney function: potential implications in patients with heart failure.
Topics: Adenosine; Animals; Heart Failure; Humans; Kidney; Kidney Tubules, Collecting; Kidney Tubules, Proximal; Receptors, Purinergic P1; Reperfusion Injury; Vasoconstriction; Vasopressins; Xanthines | 2008 |
2 trial(s) available for cvt 124 and Cardiac Failure
| Article | Year |
|---|---|
Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure.
Topics: Adult; Aged; Diuretics; Double-Blind Method; Female; Furosemide; Glomerular Filtration Rate; Heart Failure; Humans; Kidney Function Tests; Male; Middle Aged; Natriuresis; Purinergic P1 Receptor Antagonists; Receptors, Purinergic P1; Water-Electrolyte Balance; Xanthines | 2000 |
BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Creatinine; Cross-Over Studies; Diuresis; Diuretics; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Electrolytes; Female; Furosemide; Glomerular Filtration Rate; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Purinergic P1 Receptor Antagonists; Sodium; Urinalysis; Xanthines | 2002 |
1 other study(ies) available for cvt 124 and Cardiac Failure
| Article | Year |
|---|---|
Cardiorenal effects of adenosine subtype 1 (A1) receptor inhibition in an experimental model of heart failure.
Topics: Animals; Heart Failure; Hemodynamics; Kidney; Male; Purinergic P1 Receptor Antagonists; Swine; Xanthines | 2002 |